Vor BioPharma Halts Trials, Lays Off 95% of Workforce
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
Vor BioPharma Inc (NASDAQ: VOR) is a clinical-stage biotechnology company focused on cell and genome engineering to treat blood cancers. Founded by Dr. Siddhartha Mukherjee, the company’s proprietary platform combines hematopoietic stem cell biology, genome editing, and CAR-T cells to create therapies that aim to protect healthy blood cells while targeting malignant cells.
Corporate Structure and Leadership
Vor Bio’s leadership team includes professionals with experience in biopharmaceuticals and clinical settings. The Board of Directors has extensive industry knowledge, while scientific and clinical advisors provide expertise in hematology and cell therapy. As of May 2025, the company announced a workforce reduction affecting approximately 95% of its staff, with eight employees remaining to pursue strategic initiatives and alternatives.
<img src="" alt=""cell therapy"" style="width:100%;">
Pipeline and Clinical Programs
The company’s pipeline addresses acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) through multiple modalities:
- Trem-cel + Mylotarg (VBP101): A shielded transplant where donor cells are edited to remove CD33, allowing post-transplant administration of Mylotarg with reduced toxicity.
- VCAR33 (VBP301): An allogeneic CAR-T therapy derived from healthy donor cells, designed for improved expansion and persistence compared to patient-derived products.
- Trem-cel + VCAR33 Treatment System: A sequential approach that combines trem-cel transplantation with VCAR33 infusion post-transplant.
- VADC45: A CD45-directed antibody-drug conjugate being investigated as a conditioning agent and for treating hematologic malignancies.
- CD33-CLL1 Treatment System: A dual-targeted platform that pairs multiplex-edited hematopoietic stem cells with a bispecific CAR-T therapy.
Recent Developments and Strategic Review
On May 8, 2025, Vor Bio announced the cessation of its clinical and manufacturing operations, resulting in layoffs of approximately 95% of its workforce and the halting of all ongoing clinical trials. The Board of Directors initiated a process to explore strategic alternatives, which may include asset divestiture, licensing agreements, a potential sale, or a merger. In connection with this process, the company filed multiple Form 8-K reports on May 20 and May 23, 2025, and a first-quarter 2025 Form 10-Q on May 14, 2025.
Financial and Stock Performance
Vor Bio has been in a cash-burn cycle without any commercial products approved to date. Key stock metrics as of June 24, 2025:
| Metric | Value |
|---|---|
| Last Price | $0.4341 (+49.69%) |
| Volume | 22,760,372 |
| 52-Week Range | $0.13 – $1.80 |
| Market Capitalization | $53.4 million |
| Year-to-Date Change | –62.16% |
The first-quarter 2025 Form 10-Q indicated ongoing research and development expenditures, general and administrative costs, and a net loss typical of early-stage biopharma companies.
Market Position and Industry Context
Vor Bio operates within the cell and gene therapy sector, which is characterized by high risk and significant capital requirements. In the first quarter of 2025, Fierce Biotech reported 63 biotech layoff rounds, with nearly one-third occurring at cell and gene therapy companies. Challenges in fundraising and competition from larger oncology and hematology firms have led to strategic shifts in this sector.
tl;dr
On May 8, 2025, Vor BioPharma halted its cell therapy trials and laid off approximately 95% of staff, retaining eight employees to explore strategic alternatives, which may include asset sales or a merger. The company’s shares traded at $0.4341 on June 24, 2025, reflecting a 49.69% increase, while pursuing options to maximize shareholder value. Future developments will depend on the outcomes of the strategic review.